We recently compiled a list of the Cramer’s Morning Thoughts: 20 Stocks to Watch. In this article, we are going to take a look at where Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stands against the other stocks to watch according to Jim Cramer. In a recent episode of Mad Money, Jim Cramer explains that if you’re investing with […]
(Bloomberg) -- Regeneron Pharmaceuticals Inc. shares are headed for their biggest monthly drop since mid-2019 after a legal setback that opens the door to an early launch of a competing therapy to the drugmaker’s blockbuster eye treatment, Eylea.Most Read from BloombergClimate Migrants Stand to Overwhelm World’s MegacitiesVanderbilt Leases Struggling NYC Seminary for Campus ExpansionNew Rowhouses in London That Offer a Bridge to the 19th CenturyNJ Transit, Amtrak Trains Delayed After Derailment
Regeneron stock rose Friday after the company won FDA approval for Dupixent in chronic obstructive pulmonary disease, or COPD.